Services: Belgium-based global biopharmaceutical company specializing in central nervous system (CNS) and immunology diseases. Marketed products include Cimzia (immunology), Keppra, Vimpat, Briviact (epilepsy), and Rystiggo (myasthenia gravis). Active R&D pipeline in neurology, immunology, and rare diseases. Leadership: CEO (Cyril) - headquartered in Brussels, Belgium. EVP/Head of Neurology Charl van Zyl (departed for Lundbeck CEO role 2023). Keywords: Belgian biopharma, CNS, immunology, epilepsy, myasthenia gravis, Cimzia, Briviact
Company Info
Upcoming Milestones & Key Dates
Q2 2026 earnings call
Recent News
UCB announced that Epilepsia Open published findings from a post hoc analysis of FINTEPLA (fenfluramine) effectiveness and safety, including dose changes over time, in patients with Lennox-Gastaut syndrome.
UCB beats sales forecast, but stock falls on concern guidance may be too rosy. Reported by Endpoints News on 2026-07-30.
UCB shares fall despite guidance upgrade as CEO flags higher H2 costs
Leadership Team
Careers & Job Openings